From treating inherited and progressive diseases to restoring loss of function, the landscape of cell and gene therapy is rapidly evolving, offering new possibilities for the treatment of a wide range of clinical indications. Current approved therapies have shown their effectiveness for treating blindness, cancer, neurological disorders, and sickle cell disease among others. In this rapidly evolving field, a preclinical safety and toxicology package is determined on a case-by-case basis. At KreaMedica, we can help you determine the needs of your preclinical package and execute the preclinical program necessary to support your advancement into the clinic.
I have had the pleasure of working with KreaMedica on several programs. They proactively identified and addressed issues and provided regular updates to ensure everyone was on the same page. Their attention to detail and willingness to take ownership of the project’s success makes them invaluable partners. They are great to work with, and I would highly recommend them to anyone looking for a drug development partner.
They supplemented and filled in gaps in our internal network and worked well with our advisors. They truly wanted to contribute to and be part of the project’s success. I highly recommend Claude, Poulomee, and Rudi as reliable partners for planning and executing toxicological and bioanalytical projects.
I have worked with KreaMedica for many years, and I must credit them for the team’s talent, professionalism, and chemistry. That doesn’t happen by accident. As a consultant, I rely on them as the first line to monitor studies and provide proactive solutions when required.